11:58 AM EST - Oncolytics Biotech Inc. : announced that following submission to the U.S. Food and Drug Administration for review, the company is initiating a U.S. Phase I study of REOLYSIN in combination with FOLFIRI in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer. Oncolytics Biotech Inc.
shares T.ONC are trading down $0.07 at $2.95.
